Evidence map›Paper›PMID 33002231›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2021

Differences in the Presentation and Progression of Parkinson's Disease by Sex.

Hirotaka Iwaki, Cornelis Blauwendraat, Hampton L Leonard, Mary B Makarious, Jonggeol J Kim, Ganqiang Liu, Jodi Maple-Grødem, Jean-Christophe Corvol, Lasse Pihlstrøm, Marlies van Nimwegen and 38 more

Open access · bronzeAbstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 4 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 4 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Observational
  8. Gender differences in non-motor symptoms in Parkinson's disease: a multicenter longitudinal study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  9. Review
  10. Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  11. Article
  12. Differentiating between the impact of sex and gender in Parkinson's disease: utilising these to advance current understanding and care practices.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  13. Article
  14. Sex and gender-related differences in neurological diseases: current challenges and recommendations for clinical practice.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  15. Repurposing dipeptidyl peptidase-4 inhibitor for Parkinson's disease prevention: A drug-target Mendelian randomization study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Observational

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

48 authors at 20 institutions in 7 countries.

Hirotaka IwakiLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-8982-7885
Cornelis BlauwendraatLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Hampton L LeonardLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Mary B MakariousLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Jonggeol J KimLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Ganqiang LiuSchool of Medicine, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-1921-9542
Jodi Maple-GrødemThe Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
Jean-Christophe CorvolAssistance-Publique Hôpitaux de Paris, ICM, INSERM UMRS 1127, CNRS 7225, ICM, Department of Neurology and CIC Neurosciences, Pitié-Salpêtrière Hospital, Paris, France.
Lasse PihlstrømDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Marlies van NimwegenDepartment of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands.
Luba SmolenskyThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Ninad AmondikarThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Samantha J HuttenThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Mark FrasierThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Khanh-Dung H NguyenTranslational Genome Sciences, Biogen, Cambridge, Massachusetts, USA.
Jacqueline RickDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Shirley EberlyDepartment of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA.
Faraz FaghriLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Peggy AuingerDepartment of Neurology, Center for Health + Technology, University of Rochester, Rochester, New York, USA.
Kirsten M ScottDepartment of Clinical Neurosciences, University of Cambridge, John van Geest Centre for Brain Repair, Cambridge, UK.
Ruwani WijeyekoonDepartment of Clinical Neurosciences, University of Cambridge, John van Geest Centre for Brain Repair, Cambridge, UK.
Vivianna M Van DeerlinDepartment of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Dena G HernandezLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Raphael J GibbsLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Aaron G Day-WilliamsFlagship Labs 60 Inc, Cambridge, Massachusetts, USA.
Alexis BriceInstitut du cerveau et de la moelle épinière ICM, Paris, France.
Guido AlvesThe Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
Alastair J NoycePreventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.ORCID 0000-0003-3027-5497
Ole-Bjørn TysnesDepartment of Neurology, Haukeland University Hospital, Bergen, Norway.
Jonathan R EvansDepartment of Neurology, Nottingham University NHS Trust, Nottingham, UK.
David P BreenCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK.
Karol EstradaTranslational Genome Sciences, Biogen, Cambridge, Massachusetts, USA.
Claire E WegelDepartment of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana, USA.
Fabrice DanjouInstitut du cerveau et de la moelle épinière ICM, Paris, France.
David K SimonDepartment of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Ole A AndreassenNORMENT; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Bernard RavinaVoyager Therapeutics, Cambridge, Massachusetts, USA.
Mathias ToftDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Peter HeutinkGerman Center for Neurodegenerative Diseases-Tubingen, Tuebingen, Germany.
Bastiaan R BloemDepartment of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands.
Daniel WeintraubDepartment of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-0633-7168
Roger A BarkerDepartment of Clinical Neurosciences and WT-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Caroline H Williams-GrayDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID 0000-0002-2648-9743
Bart P van de WarrenburgDepartment of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands.
Jacobus J Van HiltenDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Clemens R ScherzerAdvanced Center for Parkinson's Disease Research, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Andrew B SingletonLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Mike A NallsLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
National Institutes of Health · USMichael J. Fox Foundation · USBiogen (United States) · USOslo University Hospital · NORadboud University Nijmegen · NLUniversity of Cambridge · GBUniversity of Pennsylvania · USBrigham and Women's Hospital · USStavanger University Hospital · NOBeth Israel Deaconess Medical Center · USCentre National de la Recherche Scientifique · FRGerman Center for Neurodegenerative Diseases · DEHaukeland University Hospital · NOIndiana University Indianapolis · USInserm · FRInstitut du Cerveau · FRLeiden University Medical Center · NLMRC Centre for Regenerative Medicine · GBNottingham University Hospitals NHS Trust · GBQueen Mary University of London · GB

Funding

ZOVIRAX CREAM TO TREAT HERPES LABIALIS IN ADOLESCENTSM01RR000827 · NCRR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAAS, RICHARD H · 1985 to 2010
$74.3M
ZACOPRIDE VS METOCLOPRAMIDE--EFFECT ON LOWER ESOPHAGEAL SPHINCTERM01RR000847 · NCRR · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI ALTES, TALISSA A · 1985 to 2010
$48.1M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
ZINC GLUCONATE GLYCINE LOZENGES &VITAMIN C EFFECTS ON COMMON COLDM01RR000042 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELSTROM, REBECCA L · 1985 to 2007
$40.8M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI HALL, JANET E · 1985 to 2008
$37.4M
YOUTH, Osteoporosis, and Understanding Total Health (YOUTH)M01RR000334 · NCRR · OREGON HEALTH & SCIENCE UNIVERSITY · PI DORSA, DANIEL MICHAEL · 1985 to 2006
$30.6M
ZOLEDRONIC ACID IN PROSTATE CANCERM01RR000645 · NCRR · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI COLTEN, HARVEY R · 1985 to 2006
$27.0M
YOGA FOR THE MANAGEMENT OF HIV-METABOLIC SYNDROMESM01RR000036 · NCRR · WASHINGTON UNIVERSITY · PI REEDS, DOMINIC N · 1985 to 2007
$25.4M
Supplemental Funding to the NET PD StudiesU01NS043128 · NINDS · UNIVERSITY OF ROCHESTER · PI KIEBURTZ, KARL D. · 2001 to 2014
$24.2M
YOGA, IMMUNE FUNCTION, AND HEALTHM01RR000034 · NCRR · OHIO STATE UNIVERSITY · PI PASKETT, ELECTRA D. · 1985 to 2008
$22.7M
XANTHINE OXIDASE PRODUCTS IN MODULATION OF ENDOTHELIAL DYSFUNCTIONM01RR000059 · NCRR · UNIVERSITY OF IOWA · PI FAKHRY, ALI · 1985 to 2007
$22.3M
ZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1M
Department of HealthIntramural NIH HHS Z01 AG000949NCRR NIH HHS M01 RR000034NCRR NIH HHS M01 RR000036NCRR NIH HHS M01 RR000040NCRR NIH HHS M01 RR000042NCRR NIH HHS M01 RR000044NCRR NIH HHS M01 RR000059NCRR NIH HHS M01 RR000334NCRR NIH HHS M01 RR000645NCRR NIH HHS M01 RR000827NCRR NIH HHS M01 RR000847NCRR NIH HHS M01 RR001066NIA NIH HHS P50 AG005134NIA NIH HHS U19 AG062418NINDS NIH HHS R01 NS024778NINDS NIH HHS R01 NS115144NINDS NIH HHS U01 NS043128NINDS NIH HHS U01 NS050095NINDS NIH HHS U01 NS082157NINDS NIH HHS U01 NS100603
6 · The paper itself

Abstract

backgroundPrevious studies reported various symptoms of Parkinson's disease (PD) associated with sex. Some were conflicting or confirmed in only one study.

objectivesWe examined sex associations to PD phenotypes cross-sectionally and longitudinally in large-scale data.

methodsWe tested 40 clinical phenotypes, using longitudinal, clinic-based patient cohorts, consisting of 5946 patients, with a median follow-up of 3.1 years. For continuous outcomes, we used linear regressions at baseline to test sex-associated differences in presentation, and linear mixed-effects models to test sex-associated differences in progression. For binomial outcomes, we used logistic regression models at baseline and Cox regression models for survival analyses. We adjusted for age, disease duration, and medication use. In the secondary analyses, data from 17 719 PD patients and 7588 non-PD participants from an online-only, self-assessment PD cohort were cross-sectionally evaluated to determine whether the sex-associated differences identified in the primary analyses were consistent and unique to PD.

resultsFemale PD patients had a higher risk of developing dyskinesia early during the follow-up period, with a slower progression in activities of daily living difficulties, and a lower risk of developing cognitive impairments compared with male patients. The findings in the longitudinal, clinic-based cohorts were mostly consistent with the results of the online-only cohort.

conclusionsWe observed sex-associated contributions to PD heterogeneity. These results highlight the necessity of future research to determine the underlying mechanisms and importance of personalized clinical management. © 2020 International Parkinson and Movement Disorder Society.

Indexed as

Cognitive DysfunctionParkinson DiseaseActivities of Daily LivingCohort StudiesDisease ProgressionFemaleHumansMaleParkinson's disease; gender; sex; dyskinesias; cognitive impairment; activities of daily livings

Identifiers

PMID33002231
PMCPMC7883324
OpenAlexW3091514793

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.